New Jersey headquartered $2.1 bn Amneal Pharmaceuticals is now betting on specialised and differentiated products to build its presence in the Indian pharmaceutical market (IPM), as it eyes $ 1 bn revenues by 2030 from non-US geographies.
Founded by two Indian-origin brothers Chirag and Chintu Patel in 2002, Amneal is the fifth largest generics player in the US market by prescriptions, and has begun commercial operations in India from October last year. It has had presence through manufacturing and R&D footprint in India since 2008, and currently has five formulations and two active pharmaceutical ingredients (API) plants here.
Currently, Amneal